glandular and epithelial neoplasms

Summary

Summary: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.

Top Publications

  1. Berkenblit A, Cannistra S. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2005;50:426-38 pubmed
  2. Burger R, Sill M, Monk B, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-71 pubmed
    ..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...
  3. Cannistra S, Matulonis U, Penson R, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6 pubmed
  4. Lurie G, Wilkens L, Thompson P, McDuffie K, Carney M, Terada K, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566-71 pubmed
    ..1 and OR 5.2, 95% CI 1.6-17.5), but not in Japanese women (OR 1.1, 95% CI 0.6-1.9 and OR 2.3, 95% CI:0.4-12.3). This investigation provides some evidence that polymorphisms in the VDR gene might influence ovarian cancer susceptibility...
  5. Giordano G, Azzoni C, D Adda T, Rocco A, Gnetti L, Froio E, et al. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Pathol Res Pract. 2008;204:163-74 pubmed publisher
  6. Azad N, Annunziata C, Steinberg S, Minasian L, Premkumar A, Chow C, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008;112:1726-32 pubmed publisher
    ..In this pilot study, the authors analyzed the utility of CA125 to predict disease behavior in patients who were receiving sorafenib, a Raf-kinase/VEGFR2 inhibitor, and bevacizumab, an anti-VEGF monoclonal antibody...
  7. Rejniak K, Anderson A. A computational study of the development of epithelial acini: II. Necessary conditions for structure and lumen stability. Bull Math Biol. 2008;70:1450-79 pubmed publisher
    ..Whenever possible, we compare our computational results with known experimental cases of mutant acini...
  8. Quinn J, James C, Stewart G, Mulligan J, White P, Chang G, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13:7413-20 pubmed
    ..We investigated whether BRCA1 mRNA expression levels may represent a biomarker of survival in sporadic epithelial ovarian cancer following chemotherapy treatment...
  9. Tworoger S, Gertig D, Gates M, Hecht J, Hankinson S. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer. 2008;112:1169-77 pubmed publisher
    ..Therefore, the associations between these exposures and ovarian cancer risk were prospectively examined among 110,454 women in the Nurses' Health Study (NHS) for the smoking analyses and 80,253 women for the dietary analyses...

More Information

Publications107 found, 100 shown here

  1. Amin M, Gupta R, Ondrej H, McKenney J, Michal M, Young A, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol. 2009;33:393-400 pubmed publisher
    ..Thyroid-like follicular renal cell carcinoma represents a unique histologic subtype of renal cell carcinoma of low malignant potential and its primary importance is to distinguish it from metastatic carcinoma from the thyroid...
  2. Kikkawa F, Nawa A, Ino K, Shibata K, Kajiyama H, Nomura S. Advances in treatment of epithelial ovarian cancer. Nagoya J Med Sci. 2006;68:19-26 pubmed
    ..The effectiveness of neoadjuvant chemotherapy and interval debulking surgery still remains unclear. This review will describe the advances in surgical procedures and chemotherapy in treatment of ovarian cancer patients...
  3. Christie M, Oehler M. Molecular pathology of epithelial ovarian cancer. J Br Menopause Soc. 2006;12:57-63 pubmed
    ..The identified molecular changes and pathways of development in epithelial ovarian cancer will facilitate the rationalized development of new diagnostic modalities and tailored therapies for this malignancy...
  4. Chan J, Cheung M, Husain A, Teng N, West D, Whittemore A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108:521-8 pubmed
    ..To estimate the change in survival rates of women with ovarian cancer during the past 14 years...
  5. Chan J, Munro E, Cheung M, Husain A, Teng N, Berek J, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007;109:12-9 pubmed
    ..To estimate the survival impact of lymphadenectomy in women diagnosed with clinical stage I ovarian cancer...
  6. Licchesi J, Westra W, Hooker C, Machida E, Baylin S, Herman J. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 2008;29:895-904 pubmed publisher
    ..64 and 48.17. These results show that gene silencing of Wnt antagonists by promoter hypermethylation occurs during the earliest stages of glandular neoplasia of the lung and accumulates with progression toward malignancy. ..
  7. Bazant Hegemark F, Stone N. Towards automated classification of clinical optical coherence tomography data of dense tissues. Lasers Med Sci. 2009;24:627-38 pubmed publisher
    ..The interest of the presented methods lies in the prospect of objective, quick, and/or post-acquisition processing. There is a potential to improve clinical decision making based on automated processing of OCT data. ..
  8. Brüning A, Burger P, Vogel M, Rahmeh M, Gingelmaiers A, Friese K, et al. Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol Ther. 2009;8:226-32 pubmed
    ..Because nelfinavir represents an already approved drug for use in humans with HIV infection, it could rapidly be tested in clinical studies as a potential treatment strategy against drug-resistant ovarian cancer. ..
  9. Brenner J, Chinnaiyan A. Translocations in epithelial cancers. Biochim Biophys Acta. 2009;1796:201-15 pubmed publisher
    ..Here, the molecular mechanisms of gene fusions that drive several epithelial cancers and the recent technological advances that increase the speed and reliability of recurrent gene fusion discovery are explored. ..
  10. Kortun C, Hijazi Y, Arifler D. Combined Monte Carlo and finite-difference time-domain modeling for biophotonic analysis: implications on reflectance-based diagnosis of epithelial precancer. J Biomed Opt. 2008;13:034014 pubmed publisher
    ..The results presented need to be taken into account when developing photon propagation models or implementing inverse algorithms to extract optical properties from measurements. ..
  11. Mateus C, Robert C. [Epithelial and melanic skin tumours]. Rev Prat. 2007;57:2067-79 pubmed
  12. Roby K, Niu F, Rajewski R, Decedue C, Subramaniam B, Terranova P. Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax. Adv Exp Med Biol. 2008;622:169-81 pubmed
  13. Nishiyama H, Isomoto H, Yamaguchi N, Fukuda E, Ikeda K, Ohnita K, et al. Endoscopic submucosal dissection for colorectal epithelial neoplasms. Dis Colon Rectum. 2010;53:161-8 pubmed publisher
    ..The prognosis of early colorectal cancer in patients treated by endoscopic submucosal dissection is likely to be excellent, although further longer follow-up studies are warranted. ..
  14. Moore R, MacLaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol. 2010;22:492-7 pubmed publisher
    ..Recently, novel biomarkers have become available clinically that improve upon the use of CA125 for the risk assessment and management of women with ovarian cancer. ..
  15. Leonards L, Pahwa A, Patel M, Petersen J, Nguyen M, Jude C. Neoplasms of the Appendix: Pictorial Review with Clinical and Pathologic Correlation. Radiographics. 2017;37:1059-1083 pubmed publisher
    ..Novel treatments such as hyperthermic intraperitoneal chemotherapy have increased survival for patients with mucinous tumors. ©RSNA, 2017...
  16. Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, et al. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer. 2007;97:1124-34 pubmed
    ..0001 in both relationships). In conclusion, MCM-2 and MCM-5 proteins appear to be promising as prognostic markers in patients with ovarian adenocarcinomas. ..
  17. Rema P, Suchetha S, Mathew A, Mathew A, Sebastian P. Secondary cytoreduction in epithelial ovarian cancer recurrence: a perspective from a regional cancer center in India. J Reprod Med. 2009;54:506-10 pubmed
    ..25% The present data show that a macroscopically complete salvage surgical cytoreduction is possible for most patients with recurrent epithelial ovarian cancer and confers a definite survival benefit to the patient. ..
  18. Kim J, Kim G, Lee B, Park C, Jeon H, Baek D, et al. Endoscopic submucosal dissection for esophagogastric junction tumors: a single-center experience. Surg Endosc. 2018;32:760-769 pubmed publisher
    ..ESD is an effective, safe, and feasible treatment for EGJ epithelial neoplasms. However, the complete resection rate decreases for tumors with ulceration. ..
  19. Millimaggi D, Mari M, D Ascenzo S, Carosa E, Jannini E, Zucker S, et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007;9:349-57 pubmed
    ..We therefore conclude that vesicles shed by ovarian cancer cells may induce proangiogenic activities of HUVECs by a CD147-mediated mechanism. ..
  20. Alvero A, Montagna M, Mor G. Correlation of caspase activity and in vitro chemo-response in epithelial ovarian cancer cell lines. Methods Mol Biol. 2008;414:79-82 pubmed
    ..Our findings demonstrate that the use of the Caspase-Glotrade mark assay allows a simple, fast, and sensitive alternative for the evaluation of in vitro response to chemotherapy. ..
  21. Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol. 2010;66:203-7 pubmed publisher
    ..Although the occurrence of serious adverse events might have emerged at random, a detrimental effect of preoperative study medication could not be denied. Further evaluations of sorafenib in ovarian cancer are warranted. ..
  22. Kim H, Park N, Chung H, Kim J, Song Y, Kang S. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87:1136-42 pubmed publisher
    ..Furthermore, it can be helpful in selecting patients who should undergo systemic lymphadenectomy for the detection of hidden lymph node metastasis. ..
  23. Thiryayi S, Marshall J, Rana D. An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia. Cytopathology. 2010;21:223-8 pubmed publisher
    ..3% for SP and 88.4% combined. The overall pick-up rates for the two methods were significantly different (TP 0.031%, SP 0.052%; P = 0.014). Histology showed only CIN3 with endocervical crypt involvement in nine TP cases and one SP case. ..
  24. Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010;70:1616-24 pubmed publisher
    ..Therefore, it is conceivable that annexin A3 could be a target for therapeutic intervention and may also serve as a biomarker for drug resistance in ovarian cancer patients. ..
  25. Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, et al. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer. 2015;89:306-10 pubmed publisher
    ..6 for other targeted therapies. Phase I trials appear as a sound therapeutic option in TENs pts progressing after standard treatments. Use of AA and mTORi seem to yield a good clinical response and warrant further investigation. ..
  26. Hennessy B, Coleman R, Markman M. Ovarian cancer. Lancet. 2009;374:1371-82 pubmed publisher
  27. Shinya T, Tanaka T, Soh J, Matsushita T, Sato S, Toyooka S, et al. Diagnostic Value of Dual-time-point F-18 FDG PET/CT and Chest CT for the Prediction of Thymic Epithelial Neoplasms. Acta Med Okayama. 2017;71:105-112 pubmed publisher
    ..853. Delayed scanning could improve the diagnostic capacity for carcinoma. The T/M ratio and mediastinal fat infiltration are predictive of carcinoma with moderate diagnostic accuracy. ..
  28. Cogle C, Theise N, Fu D, Ucar D, Lee S, Guthrie S, et al. Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells. 2007;25:1881-7 pubmed
    ..Disclosure of Potential Conflicts of Interest is found at the end of this article. ..
  29. Lee E, Lee Y, Suh D, Kang J, Kim I. Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors. Appl Immunohistochem Mol Morphol. 2010;18:69-74 pubmed publisher
  30. Patil D, Chou P. Sialoblastoma: utility of Ki-67 and p53 as a prognostic tool and review of literature. Pediatr Dev Pathol. 2010;13:32-8 pubmed publisher
    ..This report highlights the potential utility of proliferation markers such as Ki-67 in concert with p53 expression to better predict the biological behavior of a rare but locally aggressive neoplasm. ..
  31. Albrecht H, Denardo G, Denardo S. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging. 2007;51:304-13 pubmed
  32. Rossing M, Cushing Haugen K, Wicklund K, Doherty J, Weiss N. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2548-56 pubmed
    ..These findings, if replicated, may have implications both for public health and development of chemoprevention strategies. ..
  33. Schneider J, Illig T, Rosenberger A, Bickeböller H, Wichmann H. Detection of ATM gene mutations in young lung cancer patients: a population-based control study. Arch Med Res. 2008;39:226-31 pubmed publisher
    ..In comparison to young lung cancer patients, ATM gene mutations had no detectable relevant modifying effect on lung cancer risk. ..
  34. Kang H, Kim N, Park Y, Hwang J, Kim J, Jeong S, et al. Effects of Helicobacter pylori Infection on gastric mucin expression. J Clin Gastroenterol. 2008;42:29-35 pubmed
    ..pylori eradication. These results suggest that H. pylori infection causes alterations of mucin expression, closely related with the development of gastric atrophy with intestinal metaplasia, probably contributing to carcinogenesis. ..
  35. Langland G, Yannone S, Langland R, Nakao A, Guan Y, Long S, et al. Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities. Oncol Rep. 2010;23:1021-6 pubmed
    ..These data suggest that the activity of regulatory molecules such as p53 may be better indicators of radiation sensitivity than DNA repair enzymes such as DNA-PK in ovarian cancer. ..
  36. Fujishiro M, Kodashima S, Goto O, Ono S, Muraki Y, Kakushima N, et al. Technical feasibility of endoscopic submucosal dissection of gastrointestinal epithelial neoplasms with a splash-needle. Surg Laparosc Endosc Percutan Tech. 2008;18:592-7 pubmed publisher
    ..The accumulation of knowledge and cases verifying its usefulness is necessary, and a study comparing the knife with first-generation endosurgical knives is also warranted. ..
  37. Yang W, Le Petross H, Macapinlac H, Carkaci S, Gonzalez Angulo A, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109:417-26 pubmed
    ..Sonography can be useful in diagnosing regional nodal disease. PET/CT provides additional information on distant metastasis, and it should be considered in the initial staging of IBC. ..
  38. Bhardwaj A, Frankel W, Pellegata N, Wen P, Prasad M. Intracellular versican expression in mesenchymal spindle cell tumors contrasts with extracellular expression in epithelial and other tumors--a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2008;16:263-6 pubmed publisher
  39. Bose C. Possible role of Moringa oleifera Lam. root in epithelial ovarian cancer. MedGenMed. 2007;9:26 pubmed
  40. Nagle C, Bain C, Green A, Webb P. The influence of reproductive and hormonal factors on ovarian cancer survival. Int J Gynecol Cancer. 2008;18:407-13 pubmed
  41. Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:711-7 pubmed
    ..001). Therefore, progressive decrease in LINE-1 methylation level is a common and important epigenetic process in ovarian multistep carcinogenesis. Moreover, the COBRALINE-1 method has the potential to be used as a tumor marker for EOC. ..
  42. Zheng J, Huang J, Mao Y, Liu S, Sun X, Zhu X, et al. Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. J Biol Chem. 2009;284:13610-9 pubmed publisher
    ..These results suggest that cancer-derived Ig genes have a distinct repertoire that may have implications for their role in carcinogenesis. ..
  43. Fuchs A, Hartmann S, Ernestus K, Mutzbauer G, Linz C, Brands R, et al. Mandibular intraosseous pseudocarcinomatous hyperplasia: a case report. J Med Case Rep. 2016;10:268 pubmed
    ..A misinterpretation of pseudocarcinomatous hyperplasia as squamous cell carcinoma must be avoided because it can lead to a massive overtreatment. ..
  44. Palmer C, Duan X, Hawley S, Scholler N, Thorpe J, Sahota R, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE. 2008;3:e2633 pubmed publisher
    ..Also, we discussed the limitations of studies (like this one) that use samples obtained from symptomatic women to assess potential utility in detection of disease months to years prior to clinical detection. ..
  45. Snaathorst J, Sewnaik A, Paridaens D, de Krijger R, van der Meij E. Primary epithelial tumors of the lacrimal gland; a retrospective analysis of 22 patients. Int J Oral Maxillofac Surg. 2009;38:751-7 pubmed publisher
    ..Malignant tumors have a short duration of symptoms, are sometimes mistaken for inflammatory disease, and are, even in case of aggressive surgery, characterized by a high rate of local recurrence and metastasis. ..
  46. Mohanty S, Parwani A. Mixed epithelial and stromal tumors of the kidney: an overview. Arch Pathol Lab Med. 2009;133:1483-6 pubmed publisher
    ..Recently a case with translocation t(1;19) has been described. This article provides a brief overview of the current knowledge of mixed epithelial and stromal tumor of the kidney...
  47. Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol. 2010;21:1168-72 pubmed publisher
    ..Although our results are preliminary, CAP-GEM shows activity and safety in pretreated TETs. Furthermore, multicenter trials, also in first-line setting, are necessary to confirm our results. ..
  48. Thway K, Robertson D, Jones R, Selfe J, Shipley J, Fisher C, et al. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. Br J Cancer. 2016;115:473-9 pubmed publisher
    ..Endosialin expression could be used to select patients for such clinical trials. Based on our results, patients with undifferentiated pleomorphic sarcoma may be particularly suitable for such a therapeutic approach. ..
  49. Kolwijck E, Span P, Thomas C, Bulten J, Sweep F, Massuger L. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. Oncol Rep. 2010;23:579-84 pubmed
  50. López F, Williams M, Cardesa A, Hunt J, Strojan P, Rinaldo A, et al. How phenotype guides management of non-conventional squamous cell carcinomas of the larynx?. Eur Arch Otorhinolaryngol. 2017;274:2709-2726 pubmed publisher
    ..Particular attention is paid to features which are at variance with the conventional SCC and how these impact on management of these rare tumors. ..
  51. Terauchi F, Nishi H, Moritake T, Kobayashi Y, Nagashima T, Onodera T, et al. Prognostic factor on optimal debulking surgery by maximum effort for stage IIIC epithelial ovarian cancer. J Obstet Gynaecol Res. 2009;35:315-9 pubmed
    ..The aim of this study was to assess the prognostic factor of radical surgery in patients with stage IIIc ovarian cancer...
  52. Beesley J, Jordan S, Spurdle A, Song H, Ramus S, Kjaer S, et al. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev. 2007;16:2557-65 pubmed
    ..Further analyses of SNPs in this gene are therefore warranted to determine whether SRD5A2 plays a role in ovarian cancer predisposition...
  53. Matsui Y, Watanabe J, Ikegawa M, Kamoto T, Ogawa O, Nishiyama H. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Oncogene. 2008;27:4603-14 pubmed publisher
    ..We expect that cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide may effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer...
  54. Cao L, Petrusca D, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008;29:1893-900 pubmed publisher
    ..Our data show that TG2 prevents apoptosis induced by cisplatin by activating the NF-kappaB survival pathway in ovarian cancer cells...
  55. Olsen C, Green A, Nagle C, Jordan S, Whiteman D, Bain C, et al. Epithelial ovarian cancer: testing the 'androgens hypothesis'. Endocr Relat Cancer. 2008;15:1061-8 pubmed publisher
    ..7; 95% CI 1.1-12.0); however, use of the androgenic medication Danazol did not increase risk (OR 1.0; 95% CI 0.4-2.9). Overall, our results do not support the hypothesis that androgen-related disorders increase the risk of ovarian cancer...
  56. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol. 2009;131:478-89 pubmed publisher
    ..K-ras mutations, significantly associated with the mucin-secreting type of adenocarcinoma, consistently predict lack of response in white patients...
  57. Honglin Yin -, Jun Du -, Zhenfeng Lu -, Xia Jiao -, Jiandong Wang -, Xiaojun Zhou -. The correlation of the World Health Organization histologic classification of thymic epithelial tumors and its prognosis: a clinicopathologic study of 108 patients from China. Int J Surg Pathol. 2009;17:255-61 pubmed publisher
    ..001) and also reflected the clinical behavior of tumors. The Masaoka stage was the most important independent prognostic index in thymomas. The WHO histologic subtype and completeness of resection were also important prognostic factors...
  58. Large M, Al Ahmadie H, Shalhav A, Zorn K. Mixed epithelial stromal renal tumor with dystrophic ossification: a case report and literature review. Can J Urol. 2009;16:4690-3 pubmed
    ..We conclude that laparoscopy may be utilized to safely perform nephron sparing surgery for select, calcified renal masses...
  59. Tong G, Yu W, Beaubier N, Weeden E, Hamele Bena D, Mansukhani M, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218-27 pubmed publisher
    ..As shown in this study, PAX8 is widely expressed in normal and neoplastic renal tissues. PAX8 may be a useful additional marker for renal epithelial tumors; however, its specificity and sensitivity await further investigation...
  60. Yanagawa M, Tomiyama N, Honda O, Kikuyama A, Sumikawa H, Koyama M, et al. CT-guided percutaneous cutting needle biopsy of thymic epithelial tumors comparison to the accuracy of computed tomographic diagnosis according to the world health organization classification. Acad Radiol. 2010;17:772-8 pubmed publisher
  61. Heiss M, Murawa P, Koralewski P, Kutarska E, Kolesnik O, Ivanchenko V, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209-21 pubmed publisher
    ..Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile...
  62. Fecker L, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156 Suppl 3:25-33 pubmed
    ..Detailed analysis of apoptosis pathways employed by diclofenac in these cells may help to improve therapeutic strategies and to overcome possible mechanisms that are involved in nonresponsiveness...
  63. Muslimani A, Kundranda M, Jain S, Daw H. Recurrent bronchial epithelial-myoepithelial carcinoma after local therapy. Clin Lung Cancer. 2007;8:386-8 pubmed
    ..Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-myoepithelial carcinoma is a tumor of low-grade malignancy...
  64. Puiffe M, Le Page C, Filali Mouhim A, Zietarska M, Ouellet V, Tonin P, et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia. 2007;9:820-9 pubmed
    ..The data support the validity of the strategy to uncover molecular events that are associated with tumor cell behavior and highlight the impact of ascites on the cellular and molecular parameters of ovarian cancer...
  65. Lhomme C, Morice P, Planchamp F, Darai E, Joly F, Leblanc E, et al. [Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer--update. According to the methodology of Standards, Options: Recommendations (SOR)]. Bull Cancer. 2008;95:881-6 pubmed publisher
    ..Following the monitoring process, we identified new data conferring sufficient elements to justify an updating of the CPG concerning the surgical, the medical fi rst-line and consolidation treatments of epithelial ovarian cancers...
  66. Fattori E, Aurisicchio L, Zampaglione I, Arcuri M, Cappelletti M, Cipriani B, et al. ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum Gene Ther. 2009;20:253-65 pubmed publisher
    ..Our findings are particularly relevant in the investigation of the impact of TAA polymorphisms on the efficacy of a cancer vaccine strategy...
  67. Jang K, Kim K, Hwang S, Kwon K, Kim K, Park H, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 2009;41:366-71 pubmed publisher
    ..Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours...
  68. Pecorelli S, Ray Coquard I, Tredan O, Colombo N, Parma G, Tisi G, et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol. 2010;21:759-65 pubmed publisher
    ..A prospective phase II study was conducted to evaluate the efficacy and toxicity of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer...
  69. Zhen L, Gui lan L, Ping Y, Jin H, Ya li W. The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance. Int J Gynecol Cancer. 2010;20:82-6 pubmed publisher
    ..H3K9Ac and H4K20TriMe were potential biomarkers for prognosis. H3K14Ac showed no significant relation with the occurrence and development of ovarian tumors. ..
  70. Schwartz N, Timor Tritsch I, Wang E. Adnexal masses in pregnancy. Clin Obstet Gynecol. 2009;52:570-85 pubmed publisher
    ..In addition, a malignancy can be present in a small minority of cases. In this article, we review the available literature on this subject to help guide the clinician in the diagnosis and management of adnexal masses in pregnancy...
  71. Karamanou M, Liappas J, Pertidou E, Androutsos G. Simon-Emmanuel Duplay (1836-1924) and the conceptions on epithelial cancers in the 19th century. J BUON. 2010;15:400-4 pubmed
    ..The studies carried out by Professor Simon Emmanuel Duplay and his contemporaries on cancer in the mid-19th century are interesting and promoted cancer research in the clinical, epidemiological, therapeutical and experimental fields...
  72. Zagouri F, Dimopoulos M, Bournakis E, Papadimitriou C. Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol. 2010;31:268-77 pubmed
    ..It is tempting to anticipate the gradual integration of molecular profiling in clinical practice...
  73. Pospísková M, Spenerová M, Pilka R, Kudela M, Hajduch M, Sramek V, et al. Repeated chemosensitivity testing in patients with epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2010;31:295-8 pubmed
  74. Turbiner J, Amin M, Humphrey P, Srigley J, de Leval L, Radhakrishnan A, et al. Cystic nephroma and mixed epithelial and stromal tumor of kidney: a detailed clinicopathologic analysis of 34 cases and proposal for renal epithelial and stromal tumor (REST) as a unifying term. Am J Surg Pathol. 2007;31:489-500 pubmed
  75. Bose C. Follicle stimulating hormone receptor (FSHR) antagonist and epithelial ovarian cancer (EOC). J Exp Ther Oncol. 2007;6:201-4 pubmed
    ..Its agonist and antagonists has remained the subject of interest to the reproductive biologists. It seems worthwhile to see what is new research on FSHR and whether they will be of any help in epithelial ovarian cancer...
  76. Bland A, Everett E, Pastore L, Andersen W, Taylor P. Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy. Int J Gynecol Cancer. 2008;18:629-36 pubmed
    ..For those patients highly likely to have an SSC, CO may be offered as a reasonable alternative, decreasing the morbidity of an extensive surgical procedure that may not provide survival benefit...
  77. Downs L, Judson P, Argenta P, Ghebre R, Geller M, Bliss R, et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer. 2008;112:331-9 pubmed
    ..Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide...
  78. Capizzi E, Gabusi E, Grigioni A, De Iaco P, Rosati M, Zamagni C, et al. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Diagn Mol Pathol. 2008;17:34-8 pubmed publisher
    ..Patients with clinical complete or partial response underwent radical hystero-oophorectomy, omentectomy, and lymphadenectomy and were followed up every 3 to 6 months...
  79. Toyooka S, Kishimoto T, Date H. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama. 2008;62:1-7 pubmed
    ..In terms of future tasks, it will be necessary to apply the knowledge that is learned about molecular alterations to clinical practice and to further elucidate the pathogenesis of MM with extensive research...
  80. Serin I, Tanriverdi F, Yilmaz M, Ozcelik B, Unluhizarci K. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol. 2008;24:117-21 pubmed publisher
  81. Cheng L, Zhang S, MacLennan G, Lopez Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009;40:10-29 pubmed publisher
  82. Camuzcuoglu H, Arioz D, Toy H, Kurt S, Celik H, Aksoy N. Assessment of preoperative serum prolidase activity in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2009;147:97-100 pubmed publisher
    ..The aim of this study was to evaluate preoperative serum prolidase activity, total oxidant status (TOS), and total antioxidant capacity (TAC) in patients with newly diagnosed epithelial ovarian cancer (EOC)...
  83. Park J, Eom J, Kim D, Kim J, Kim Y, Kim Y, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2010;101:418-24 pubmed publisher
    ..To assess the surgical and survival outcomes after secondary cytoreductive surgery (SCRS) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC) and to identify patients who would most benefit from SCRS...
  84. Gonzalez Martin A, Toledo G, Chiva L. Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. Clin Transl Oncol. 2010;12:418-30 pubmed publisher
    ..For this reason, there is still a need for new treatments and strategies in the first-line setting...
  85. Cai H, Zhou Y, Chen H, Hou H. The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clin Oncol (R Coll Radiol). 2007;19:757-62 pubmed
    ..To assess the efficiency and morbidity associated with bowel resection with the initial cytoreduction procedure for advanced ovarian cancer...
  86. Lim S, Smith P, Syed N, Coens C, Wong H, van der Burg M, et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer. 2008;98:1452-6 pubmed publisher
    ..There was no association with overall survival. This study does not support methylation-dependent silencing of FANCF as a mechanism of sensitisation to platinum-based chemotherapy in ovarian cancer...
  87. Kim B, Cho B, Choi H, Sohn J, Park M, Chang J, et al. A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. Oncol Rep. 2008;19:1525-31 pubmed
    ..To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations...
  88. Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano T, Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab. 2008;93:3286-94 pubmed publisher
  89. Juretzka M, Hensley M, Tew W, Konner J, Aghajanian C, Leitao M, et al. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol. 2008;29:568-72 pubmed
    ..To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR)...
  90. Goudge C, Li Z, Downs L. The influence of intraoperative tumor rupture on recurrence risk in Stage Ic epithelial ovarian cancer. Eur J Gynaecol Oncol. 2009;30:25-8 pubmed
    ..We hypothesized that tumor rupture is a less ominous prognosticator in early-stage epithelial ovarian cancer than malignant washings or ovarian surface invasion...
  91. Lee Y, Choi E, Kim M, Park P, Park N, Lee H. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer. 2009;101:504-10 pubmed publisher
    ..As ovarian cancers frequently exhibit chromosome instability, we aimed at assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A...
  92. Teklali Y, Piolat C, Durand C, Boillot B, Pasquier D, Jacquier C, et al. Mixed epithelial and stromal renal tumour in a 12-year-old boy. J Pediatr Urol. 2010;6:320-3 pubmed publisher
    ..Pathology and immunohistochemistry revealed a typical MESTK. The child was free of disease at 2-year follow up after a partial nephrectomy and tumour excision...